Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM93CA4)

Drug Name
CP-376395 Drug Info
Synonyms
CP-376395; CP 376395; 175140-00-8; UNII-5113G7FP34; 3,6-Dimethyl-N-(Pentan-3-Yl)-2-(2,4,6-Trimethylphenoxy)pyridin-4-Amine; 5113G7FP34; VIZBSVDBNLAVAW-UHFFFAOYSA-N; 1Q5; CP376395; 4k5y; SCHEMBL123421; GTPL3496; CHEMBL270948; DTXSID0047298; BDBM20966; MolPort-009-194-134; KS-00002WT7; 2-Aryloxy-4-alkylaminopyridine, 3a; ZINC14975027; AKOS015994585; 4-Pyridinamine, N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-; GD-0065; CS-7833; API0007847; compound 3a [PMID: 18288792]; HY-14130; KB-76174; CP-376,395; CP 376,395
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9862166
CAS Number
CAS 175140-00-8
TTD Drug ID
DM93CA4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Corticotropin-releasing factor receptor 1 (CRHR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telavancin DM58VQX Staphylococcus infection 1B5Y Approved [3]
Pexacerfont DMBJ15R Anxiety disorder 6B00-6B0Z Phase 2/3 [4]
SSR125543 DMGJEB8 Anxiety disorder 6B00-6B0Z Phase 2 [5]
ONO-2333Ms DMOT0WR Anxiety disorder 6B00-6B0Z Phase 2 [6]
GSK561679 DMEVARK Alcohol dependence 6C40.2 Phase 2 [7]
Tildacerfont DMAB8LH Congenital adrenal hyperplasia 5A71.01 Phase 2 [8]
GSK586529 DM5E9LX Anxiety disorder 6B00-6B0Z Phase 1 [7]
GW876008 DMAXRBI Irritable bowel syndrome DD91.0 Discontinued in Phase 2 [4]
CP-316,311 DMZ76EM Major depressive disorder 6A70.3 Discontinued in Phase 2 [4]
CRA1000 DMWMBIV Anxiety disorder 6B00-6B0Z Preclinical [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticotropin-releasing factor receptor 1 (CRHR1) TT7EFHR CRFR1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3496).
2 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J Med Chem. 2008 Mar 13;51(5):1385-92.
3 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8 Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.